Gilead Corona wonder-drug fails initial tests

Gilead Corona wonder-drug fails initial tests

Due to a mistake, a report landed on WHO’s twitter page containing data about the failure of Remdesivir.

Just at the beginning of the month, pharmaceutical giant Gilead announced that it is on its way to develop a viable treatment. Also, it pledged 1 million doses for free to people with severe symptoms.

WHO, one of the supporters of this, posted yesterday on a later-deleted tweet that: "As such, the study results are inconclusive, though trends in the data suggest a potential benefit for Remdesivir, particularly among patients treated early in the disease. We understand the available data have been submitted for peer-reviewed publication, which will provide more detailed information from this study in the near future."

The summary of the clinical trial made with the antiviral drug and a placebo, conducted on randomly assigned patients, showed that in just one month, 14% of the people who undertook Remdesivir died. Those on placebo were around 13%. A STAT report showed no significant difference between the actual drug and the placebo. The trial had a total of 237 participants, from which 158 received Remdesivir and 79 placeboes. The failure can also be associated with the lack of participants, as the initial numbers were of 453 patients.

The use of Remdesivir is debatable, as it underwent clinical trials against Ebola, but it performed worse than other available drugs. At the moment, the US National Institutes of Health conducts tests with the drug. By late May, the results should be available.

As expected, Gilead’s share dropped 5.3% during yesterday’s trading session.

Gilead’s competitor, Moderna, developed a program to find a vaccine against the novel virus. Since then, its stock went up more than 170%.


See the difference when investing with CAPEX.COM by accessing elite features:

  • Stellar custom service
  • Powerful WebTrader platform and mobile app
  • High-end integrated trading tools
  • Full license and regulation from top regulators
  • Simple and fast deposit and withdrawal options


Sources: cnn.com, businessinsider.com, marketwatch.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation. Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.